Screener
Ginkgo Bioworks DNA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The source filing: Ginkgo Bioworks’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:34 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012346
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from ATM offering | 19,469 | — | — |
| Payment of issuance costs related to ATM offering | (1,340) | — | — |
| Proceeds from exercise of stock options | — | 84 | 93 |
| Taxes paid related to net share settlement of equity awards | — | — | (23) |
| Principal payments on finance leases | (354) | (897) | (1,295) |
| Contingent consideration payment | — | (922) | (1,411) |
| Payment of equity issuance costs and other | — | (4) | (580) |
| Net cash provided by (used in) financing activities | 17,775 | (1,739) | (3,216) |
Item 16. Form 10-K Summary
FAQ
- What is Ginkgo Bioworks's stock issuance proceeds?
- Ginkgo Bioworks (DNA) reported stock issuance proceeds of $9.15M in Q4 2025.
- What is the long-term trend for Ginkgo Bioworks's stock issuance proceeds?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's stock issuance proceeds has grown at a 228.6% compound annual growth rate (CAGR), from $167K to $19.47M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Ginkgo Bioworks's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude